Skip to main content

Published locations for VERTIS CV: Ertugliflozin’s proven benefits fall short of other SGLT2 inhibitors

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. VERTIS CV: Ertugliflozin’s proven benefits fall short of other SGLT2 inhibitors

User login

  • Reset your password
  • /content/vertis-cv-ertugliflozins-proven-benefits-fall-short-other-sglt2-inhibitors
  • /clinicianreviews/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits-fall-short
  • /familypracticenews/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits-fall
  • /internalmedicinenews/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits-fall
  • /clinicalendocrinologynews/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits
  • /ecardiologynews/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits-fall-short
  • /cardiology/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits-fall-short-other
  • /endocrinology/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits-fall-short
  • /internalmedicine/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits-fall-short
  • /familymedicine/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits-fall-short
  • /type-2-diabetes-icymi/article/229031/lipid-disorders/vertis-cv-ertugliflozins-proven-benefits-fall